1h agoGuruFocusBULLISH 78Earnings
Why Is MEDLINE INC Class A (MDLN) Stock Up Today?
By the Top Tier Newswire AI Desk · August 6, 2026 at 12:24 AM ET · reviewed against 10 wire stories
MEDLINE INC Class A (MDLN) is up +15.62% in the latest session. Our newswire has captured 10 stories on MDLN across 6 sources in the last 36 hours, with AI sentiment reading bullish (avg 58/100).
Public view, delayed 4h. Every headline, price and sentiment read below — and this write-up itself — reaches Pro subscribers live. Public readers see it once it clears the delay.
MDLN stock fell 12.79% to $36.66 in Monday trading after the company cut its full-year adjusted EBITDA guidance during its Q2 2026 earnings call. The stock’s sharp decline came despite the company reporting a 12% year-over-year revenue increase to $7.7 billion and raising its organic sales outlook for 2026 to 9%-10%. The downward revision to EBITDA expectations and ongoing supply chain challenges weighed on investor sentiment.
What Happened
Medline reported Q2 2026 net sales of $7.7 billion, driven by strong demand in its medical-surgical product and supply-chain businesses. The company raised its full-year organic sales outlook but reduced its adjusted EBITDA guidance to $3.3 billion to $3.4 billion, citing the impact of the Tracy fire and U.S. tariffs. During the earnings call, CEO James Boyle highlighted the resilience of the business amid these headwinds but acknowledged the need for a more conservative EBITDA outlook. The stock’s decline followed this guidance cut, despite beating both revenue and earnings estimates.
What The Data Shows
MDLN has traded down 7.6% over the past eight sessions, from $39.70 to $36.67. Insider transactions show mixed signals, with 4 sell filings totaling $3.6 billion and 1 buy totaling $171,000 in the last 90 days. The stock currently trades within its 52-week range of $32.81 to $50.88, with a market cap of $34.2 billion and a P/E ratio of 36.8. Despite strong top-line growth, the company’s net margin remains at 3.3%, and the cut to EBITDA guidance has raised concerns about profitability.
What To Watch
The company’s updated EBITDA guidance and ongoing supply chain issues will be key to watch in the coming weeks. Investors should also monitor the breadth of coverage as the market reacts to the earnings report and any potential follow-up from analysts or institutional investors.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Public view is delayed 4 hours from real time. Not financial advice.
MDLN by the numbers
Last: $39.42Session: +15.62%7 sessions: 0.00%Coverage: 10 stories / 6 sourcesAI sentiment: 58/100 (bullish)Mkt cap: $34.2BP/E: 36.852w: $32.81 to $50.88
The headlines behind the move
2h agoSeeking AlphaBULLISH 74Earnings
Medline posts best intraday gain after Q3 beat, $1B share buybacks
Medline (MDLN) stock jumps as the company posts better-than-expected results for Q3 2026 and announces plans to buy back up to $1B shares. Read more here.
3h agoSeeking AlphaNEUTRAL 50Earnings
Medline Inc. 2026 Q3 - Results - Earnings Call Presentation
2026-11-04. The following slide deck was published by Medline Inc.
4h agoThe FlyBULLISH 58Earnings
Medline backs FY26 adjusted EBITDA view $3.3B-$3.4B
5h agoThe FlyBULLISH 74Earnings
Medline Reports Q3 Adjusted Eps 44c Consensus 35c
5h agoSEC 8-KNEUTRAL 50General
Medline Inc. (MDLN) files 8-K
Filed: 2026-11-04 AccNo: 0002046386-26-000060 Size: 580 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
5h agoBusiness InsiderNEUTRAL 54Earnings
Medline Reports Third Quarter and Nine Months 2026 Results
Third quarter net sales of $7.9 billion, an increase of 10.4% Third quarter net income of $318 million, a decrease of 1.2% Third quarter Adjusted EBITDA 1 of $1.0 billion, an increase of 11.
7h agoGlobeNewswireBEARISH 34General
MDLN Investigation Reminder: Medline Product Quality Issues Trigger Securities Fraud Investigation for Investors – Contact BFA Law if You Lost Money
Medline Product Quality Issues Trigger Securities Fraud Investigation for Investors – Contact BFA Law if You Lost Money...
1d agoSeeking AlphaNEUTRAL 50Earnings
Medline Inc. Q3 2026 Earnings Preview
Medline Inc. (MDLN) is scheduled to announce Q3 earnings results on Wednesday, November 4th, before market open. The consensus EPS Estimate is $0.35 and the con
1d agoGlobeNewswireNEUTRAL 53Product/PR
Medline announces participation in the 2026 Jefferies Global Healthcare Conference
NORTHFIELD, Ill., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Medline Inc. (“Medline”) (Nasdaq: MDLN) today announced that Jim Boyle, chief executive officer, is scheduled to present at the Jefferies Global Healthcare Conference in London on Tuesday,...
Frequently asked questions
Why is MDLN stock up today?
MEDLINE INC Class A (MDLN) is up +15.62% in the latest session. Our newswire has captured 10 stories on MDLN across 6 sources in the last 36 hours, with AI sentiment reading bullish (avg 58/100). The most recent driver: "Medline (MDLN) Shares Surge Over 10% After Q3 Earnings Beat and $1B Buyback Announcement" (GuruFocus).
Is MDLN a buy right now?
Top Tier Newswire does not give financial advice. Our AI sentiment across the last 36 hours of MDLN coverage reads 58/100 over 10 stories; treat it as a research signal and do your own diligence.
How fast does this page update?
The data sections refresh continuously as the newswire lands coverage; the written analysis is published once per trading day. Pro subscribers additionally get real-time push alerts, watchlists, and the full live terminal.
More moves explained today
- Why is CRCT up today (+49.83%)
- Why is NRIX down today (-38.75%)
- Why is KD up today (+35.20%)
- Why is DUOL up today (+34.42%)
- Why is DOX down today (-27.49%)
- Why is YOU up today (+27.46%)
Want the next move before the crowd? The live terminal streams every headline in real time with watchlist alerts, AI sentiment, and the full data stack behind this page.Get Pro Access →
More on MDLN: full news and sentiment history. Sentiment scores are AI-derived research signals, not financial advice.